During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Trending: Don’t miss out on the next NVIDIA – you can invest in the future of AI for only $10.
**This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Innovation Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. PFE
Dividend Yield: 5.88%
Barclays analyst Carter Gould maintained an Equal-Weight rating and raised the price target from $30 to $32 on July 31. This analyst has an accuracy rate of 60%.
Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and boosted the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.
Recent News: On Monday, Pfizer released top-line safety and immunogenicity results from substudy B of the ongoing pivotal MONeT Phase 3 trial,evaluating two doses of Abrysvo vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus-associated lower respiratory tract disease.
Benzinga Pro's real-time newsfeed alerted to latest PFE news.
Don’t Miss:
- Finance companies are leaving New York for this hot city. Investing in its booming real estate market has never been more accessible.
- With returns as high as 300%, it’s no wonder this asset is the investment choice of many billionaires. Uncover the secret.
- Private credit outperformed both high yield bonds and equities in the last 3 market downturns (2008, COVID and 2022). Should you be adding private credit to your portfolio?
GSK plc GSK
Dividend Yield: 3.80%
Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 70%.
Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%.
Recent News: On July 31, GSK reported second-quarter sales of $9.95 billion (7.88 billion Sterling Pounds), up 10% year-over-year and 13% on constant currency.
Benzinga Pro's charting tool helped identify the trend in GSK stock.
CVS Health Corporation CVS
Dividend Yield: 4.66%
Deutsche Bank analyst George Hill maintained a Hold rating and cut the price target from $64 to $63 on Aug. 9. This analyst has an accuracy rate of 60%.
Barclays analyst Andrew Mok maintained an Equal-Weight rating and slashed the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 66%.
Recent News: On Aug. 7, CVS Health reported mixed second-quarter earnings and cut annual profit guidance.
Benzinga Pro's signals feature notified of a potential breakout in CVS shares.
Looking For Higher-Yield Opportunities?
The current high-interest-rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through dividend stocks… Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities and Benzinga has identified some of the most attractive options for you to consider.
For instance, the Ascent Income Fund from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets. With payment priority and flexible liquidity options, the Ascent Income Fund is a cornerstone investment vehicle for income-focused investors. First-time investors with EquityMultiple can now invest in the Ascent Income Fund with a reduced minimum of just $5,000. Benzinga Readers: Earn a 1% return boost on your first EquityMultiple investment when you sign up here (accredited investors only).
Don't miss out on this opportunity to take advantage of high-yield investments while rates are high. Check out Benzinga's favorite high-yield offerings.
Read More:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
